Mission

Bringing Transformational Medicines
to Patients through Innovation

Values

Innovation
Integrity
Resilience

We Differentiate with Global Ambition

  • First-in-class and best-in-class potential
  • Immuno-oncology focus
  • Three waves of innovation

Read more

  • Innovative and advanced
  • 20 clinical and pre-clinical assets in development
  • First BLA submission in 2022

Read more

  • Over 20 BD deal transactions
  • Potential cash stream ~USD 1 billion by 2025
  • Global listings: NASDAQ and soon HKEX

Read more

Global Footprint

Awards

2021

Entrepreneur of the Year

EY

2021

Executive of the Year

Scrip Awards

2021 Company of the Year

2020 Deal of the Year

BioCentury, BayHelix

2021

Excellent Employer

T+Employer™

2021

Leading DEI X Inclusion Award

sHero

2021

Top 50 Enterprises of Technology Power

Tech Power

2021

Honoured Company & Best CFO

Institutional Investor

2020

Best Value Healthcare Companies

Sina Medical

2020

China Healthcare New Power Top 10

people.cn

2020

50 Smartest Companies

MIT Technology Review

2020

Top 10 China Biotech to Watch

FiercePharma

2019

Top 10 Immuno-Oncology Startups

GEN

* The manufacturing facility is managed by I-Mab Hangzhou entity.